RecruitingPhase 4NCT05704036
Estrogen Supplementation and Bone Health in Women With CF
Studying Cystic fibrosis-gastritis-megaloblastic anemia syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Malinda Wu, MD, MScJohns Hopkins University
- Intervention
- Transdermal estrogen(drug)
- Enrollment
- 75 target
- Eligibility
- 0-100 years · FEMALE
- Timeline
- 2023 – 2027
Study locations (1)
- Johns Hopkins, Baltimore, Maryland, United States
Collaborators
Cystic Fibrosis Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05704036 on ClinicalTrials.govOther trials for Cystic fibrosis-gastritis-megaloblastic anemia syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07071324CF Wellness ProgramJohns Hopkins University
- RECRUITINGNANCT07223255Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean DietDartmouth-Hitchcock Medical Center
- RECRUITINGNANCT07031323OnTrackCF: Engagement, Feasibility, and Acceptability StudyBoston Children's Hospital
- ACTIVE NOT RECRUITINGNCT07147803Sleep Quality in Patients With Non-cystic Fibrosis BronchiectasisAssiut University
- RECRUITINGPHASE2NCT06998043Study With Phage for CF Subjects With Pseudomonas Lung InfectionBiomX Ltd
- RECRUITINGNCT06683092Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)Boston Children's Hospital
- RECRUITINGPHASE2NCT06559150A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- RECRUITINGNCT06274840COVID-19 Antibody Responses In Cystic FibrosisPilar Azevedo
See all trials for Cystic fibrosis-gastritis-megaloblastic anemia syndrome →